N
Nicholas Han
Researcher at University of Pennsylvania
Publications - 12
Citations - 3376
Nicholas Han is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 12, co-authored 12 publications receiving 1556 citations.
Papers
More filters
Journal ArticleDOI
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
Divij Mathew,Josephine R. Giles,Amy E. Baxter,Derek A. Oldridge,Allison R. Greenplate,Jennifer E. Wu,Cécile Alanio,Leticia Kuri-Cervantes,M. Betina Pampena,Kurt D'Andrea,Sasikanth Manne,Zeyu Chen,Yinghui Jane Huang,John P. Reilly,Ariel R. Weisman,Caroline A. G. Ittner,Oliva Kuthuru,Jeanette Dougherty,Kito Nzingha,Nicholas Han,Justin Kim,Ajinkya Pattekar,Eileen C. Goodwin,Elizabeth M. Anderson,Madison E. Weirick,Sigrid Gouma,Claudia P. Arevalo,Marcus J. Bolton,Fang Chen,Simon F. Lacey,Holly Ramage,Sara Cherry,Scott E. Hensley,Sokratis A. Apostolidis,Alexander C. Huang,Laura A. Vella,Laura A. Vella,Michael R. Betts,Nuala J. Meyer,E. John Wherry +39 more
TL;DR: High-dimensional flow cytometry of hospitalized COVID-19 patients found three prominent and distinct immunotypes that are related to disease severity and clinical parameters, and a compendium of immune cell information and roadmaps for potential therapeutic interventions is provided.
Journal ArticleDOI
Comprehensive mapping of immune perturbations associated with severe COVID-19.
Leticia Kuri-Cervantes,M. Betina Pampena,Wenzhao Meng,Aaron M. Rosenfeld,Caroline A. G. Ittner,Ariel R. Weisman,R.S. Agyekum,Divij Mathew,Amy E. Baxter,Laura A. Vella,Laura A. Vella,Oliva Kuthuru,Sokratis A. Apostolidis,Sokratis A. Apostolidis,Luanne Bershaw,Jeanette Dougherty,Allison R. Greenplate,Ajinkya Pattekar,Ajinkya Pattekar,Justin Kim,Nicholas Han,Sigrid Gouma,Madison E. Weirick,Claudia P. Arevalo,Marcus J. Bolton,Eileen C. Goodwin,Elizabeth M. Anderson,Scott E. Hensley,Tiffanie K. Jones,Nilam S. Mangalmurti,Eline T. Luning Prak,E. John Wherry,Nuala J. Meyer,Michael R. Betts +33 more
TL;DR: The neutrophil to lymphocyte ratio is found to be a prognostic biomarker of disease severity and organ failure and broad innate and adaptive leukocyte perturbations that distinguish dysregulated host responses in severe SARS-CoV-2 infection and warrant therapeutic investigation.
Journal ArticleDOI
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
Rishi R. Goel,Mark M Painter,Sokratis A. Apostolidis,Divij Mathew,Wenzhao Meng,Aaron M. Rosenfeld,Kendall A. Lundgreen,Arnold Reynaldi,David S. Khoury,Ajinkya Pattekar,Sigrid Gouma,Leticia Kuri-Cervantes,Philip Hicks,Sarah Dysinger,Amanda Hicks,Harsh Sharma,Sarah Herring,Scott Korte,Amy E. Baxter,Derek A. Oldridge,Josephine R. Giles,Madison E. Weirick,Christopher M McAllister,Moses Awofolaju,Nicole Tanenbaum,Elizabeth M Drapeau,Jeanette Dougherty,Sherea Long,Kurt D'Andrea,Jacob T. Hamilton,Maura McLaughlin,Justine C. Williams,Sharon Adamski,Oliva Kuthuru,Ian Frank,Michael R. Betts,Laura A. Vella,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Scott E. Hensley,Miles P. Davenport,Paul Bates,Eline T. Luning Prak,Allison R. Greenplate,E. John Wherry,S. Adamski,Z. Alam,M. M. Addison,K. T. Byrne,A. Chandra,H. C. Descamps,Nicholas Han,Y. Kaminskiy,S. C. Kammerman,Justin Kim,A. R. Greenplate,J. T. Hamilton,N. Markosyan,J. Han Noll,D. K. Omran,A. Pattekar,E. Perkey,E. M. Prager,D. Pueschl,A. Rennels,J. B. Shah,J. S. Shilan,N. Wilhausen,A. N. Vanderbeck +70 more
TL;DR: The durability of immune memory after SARS-CoV-2 mRNA vaccination was investigated in this article, where the majority of these cells cross-binding the Alpha, Beta, and Delta variants.
Journal ArticleDOI
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
Elizabeth M. Anderson,Eileen C. Goodwin,Anurag Verma,Claudia P. Arevalo,Marcus J. Bolton,Madison E. Weirick,Sigrid Gouma,Christopher M McAllister,Shannon R. Christensen,JoEllen Weaver,Philip Hicks,Tomaz B. Manzoni,Oluwatosin Oniyide,Holly Ramage,Divij Mathew,Amy E. Baxter,Derek A. Oldridge,Allison R. Greenplate,Jennifer E. Wu,Cécile Alanio,Kurt D'Andrea,Oliva Kuthuru,Jeanette Dougherty,Ajinkya Pattekar,Justin Kim,Nicholas Han,Sokratis A. Apostolidis,Alexander C. Huang,Laura A. Vella,Laura A. Vella,Leticia Kuri-Cervantes,M. Betina Pampena,Michael R. Betts,E. John Wherry,Nuala J. Meyer,Sara Cherry,Paul Bates,Daniel J. Rader,Scott E. Hensley +38 more
TL;DR: In this paper, the authors quantified levels of SARS-CoV-2-reactive antibodies and hCoVreactive antibody in serum samples collected from 431 individuals before the COVID-19 pandemic, and then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS CoV 2.
Journal ArticleDOI
CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer.
Erin Bange,Nicholas Han,Paul Wileyto,Justin Kim,Sigrid Gouma,James Robinson,Allison R. Greenplate,Madeline A Hwee,Florence Porterfield,Olutosin Owoyemi,Karan Naik,Cathy Zheng,Michael Galantino,Ariel R. Weisman,Caroline A. G. Ittner,Emily M. Kugler,Amy E. Baxter,Olutwatosin Oniyide,R.S. Agyekum,Thomas G. Dunn,Tiffanie K. Jones,Heather M. Giannini,Madison E. Weirick,Christopher M McAllister,N. Esther Babady,Anita Kumar,Adam J Widman,Susan DeWolf,Sawsan R. Boutemine,Charlotte Roberts,Krista R Budzik,Susan Tollett,Carla Wright,Tara Perloff,Lova Sun,Divij Mathew,Josephine R. Giles,Derek A. Oldridge,Jennifer E. Wu,Cécile Alanio,Sharon Adamski,Alfred L. Garfall,Laura A. Vella,Samuel J Kerr,Samuel J Kerr,Justine V. Cohen,Randall A. Oyer,Randall A. Oyer,Ryan Massa,Ivan Maillard,Kara N. Maxwell,John P. Reilly,Peter Maslak,Robert H. Vonderheide,Jedd D. Wolchok,Scott E. Hensley,E. John Wherry,Nuala J. Meyer,Angela DeMichele,Santosha Vardhana,Ronac Mamtani,Alexander C. Huang +61 more
TL;DR: In this paper, the authors showed that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses, including those treated with anti-CD20 therapy.